Clinical trial

A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV…

NCT00000889 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00000889
Title A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
Official title A Randomized, Open-Label, Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Aldesleukin
Enrollment 72
Start date Oct 1, 1997
Primary completion Dec 1, 1999
Completion Dec 1, 1999
First posted Aug 31, 2001
Last update posted Oct 29, 2021
Countries Argentina

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies